Codex DNA to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
February 09 2022 - 8:03AM
Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop
synthetic biology systems, today announced that members of its
management team will be participating in the SVB Leerink 11th
Annual Global Healthcare Conference. An updated version of Codex
DNA’s corporate presentation will be available on Wednesday,
February 16th at 12:00 pm Eastern time / 9:00 am Pacific time.
The presentation can be accessed through a link on the investors
section of the Codex DNA website
at https://ir.codexdna.com.
About Codex DNACodex DNA is
empowering scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Codex DNA is enabling rapid, accurate, and
reproducible writing of DNA and mRNA for numerous downstream
markets. The company’s award-winning BioXp™ system consolidates,
automates, and optimizes the entire synthesis, cloning, and
amplification workflow. As a result, it delivers virtually
error-free synthesis of DNA/RNA at scale within days and hours
instead of weeks or months. Scientists around the world are using
the technology in their own laboratories to accelerate the
design-build-test paradigm for novel, high-value products for
precision medicine, biologics drug discovery, vaccine and
therapeutic development, genome editing, and cell and gene therapy.
Codex DNA is a public company based in San Diego. For more
information, visit codexdna.com.
Contact:Richard LepkeDirector of Investor
Relations(619) 840-5392RichardL@codexdna.com
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jul 2023 to Jul 2024